Hims(US:HIMS) Prnewswireยท2025-07-28 00:17Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns during the specified Class Period [1][3]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [3]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the class [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [4]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [5].